Form 4: Bristol-Myers Squibb Executive Chair Giovanni Caforio Reports Stock Transactions
SEC Form 4
Giovanni Caforio, Executive Chair of Bristol-Myers Squibb, reports transactions involving common stock and market share units, including vesting, adjustments, and shares withheld for taxes.
Summary
- Giovanni Caforio, Executive Chair of Bristol-Myers Squibb, filed a Form 4 detailing changes in beneficial ownership of company stock.
- The transactions occurred on March 10, 2024, and involve common stock and market share units.
- These include the vesting of market share units granted in 2020 and 2021, as well as the distribution of performance shares earned under the 2020-2022 Long-Term Performance Award.
- Adjustments were made to awards based on performance factors, and shares were withheld for tax payments.
- Some market share units granted in 2022 and 2023 were cancelled due to not achieving the minimum payout factor of 80%.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't contain overtly positive or negative information, but the cancellation of some market share units due to not meeting performance targets is a slightly negative signal.
Negatives
- Cancellation of market share units granted in 2022 and 2023 due to not achieving the minimum payout factor of 80%.
Future Outlook
Twenty-five percent of the market share units will vest on each of the first, second, third and fourth anniversaries of the grant date.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders and their holdings in the company.
Comparison to Industry Standards
- Executive compensation packages often include a mix of salary, stock options, restricted stock units (RSUs), and performance-based awards.
- The vesting schedules and performance metrics associated with these awards are designed to align executive incentives with shareholder value creation.
- The payout factors for market share units, ranging from 60% to 225%, are common mechanisms to incentivize executives to achieve specific performance targets.
- Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar equity-based compensation plans for their executives.
Stakeholder Impact
- Shareholders may be interested in the details of executive compensation and stock ownership.
- The vesting and distribution of shares can impact the company's share count and potentially dilute existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/10/2020 | Grant date of market share units, one-quarter of which vested on 03/10/2024. |
| 03/10/2021 | Grant date of market share units, one-quarter of which vested on 03/10/2024. |
| 03/10/2022 | Grant date of market share units, one-quarter of which were cancelled on 03/10/2024 due to the 80% minimum payout factor not being achieved. |
| 03/10/2023 | Grant date of market share units, one-quarter of which were cancelled on 03/10/2024 due to the 80% minimum payout factor not being achieved. |
| 03/10/2024 | Date of reported transactions, including vesting of market share units and distribution of performance shares. |
| 03/12/2024 | Date of signature of the Form 4 filing. |
| 03/10/2025 | Vesting date for market share units. |
| 03/10/2026 | Vesting date for market share units. |
| 03/10/2027 | Vesting date for market share units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.